Patrys Ltd
PAB
Company Profile
Business description
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.
Contact
Level 4, 100 Albert Road
South Melbourne
MelbourneVIC3205
AUST: +61 396703273
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
23
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
With increased AI spending and hopes of future data center expansion, here’s what we think of Nvidia stock.
stocks
Is this overpriced ASX share too much of a gamble?
We raise our fair value after strong results but shares are pricey.
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,539.00 | 59.10 | 0.70% |
| CAC 40 | 7,269.63 | 42.17 | -0.58% |
| DAX 40 | 19,210.81 | 52.89 | -0.27% |
| Dow JONES (US) | 43,444.99 | 305.87 | -0.70% |
| FTSE 100 | 8,063.61 | 7.58 | -0.09% |
| HKSE | 19,426.34 | 9.47 | -0.05% |
| NASDAQ | 18,680.12 | 427.53 | -2.24% |
| Nikkei 225 | 38,642.91 | 107.21 | 0.28% |
| NZX 50 Index | 12,684.88 | 8.06 | -0.06% |
| S&P 500 | 5,870.62 | 78.55 | -1.32% |
| S&P/ASX 200 | 8,285.20 | 61.20 | 0.74% |
| SSE Composite Index | 3,330.73 | 49.11 | -1.45% |